1K0 Stock Overview
IGM Biosciences, Inc., a clinical-stage biotechnology company, develops Immunoglobulin M (IgM) antibodies for the treatment of cancer and autoimmune and inflammatory diseases.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
IGM Biosciences, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$7.00 |
| 52 Week High | US$16.00 |
| 52 Week Low | US$3.68 |
| Beta | 0.25 |
| 1 Month Change | -17.65% |
| 3 Month Change | -27.46% |
| 1 Year Change | -28.21% |
| 3 Year Change | -87.72% |
| 5 Year Change | n/a |
| Change since IPO | -57.27% |
Recent News & Updates
Recent updates
Shareholder Returns
| 1K0 | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 5.3% | 0.8% | 1.2% |
| 1Y | -28.2% | -24.4% | 2.0% |
Return vs Industry: 1K0 underperformed the German Biotechs industry which returned -24.4% over the past year.
Return vs Market: 1K0 underperformed the German Market which returned 2% over the past year.
Price Volatility
| 1K0 volatility | |
|---|---|
| 1K0 Average Weekly Movement | 17.1% |
| Biotechs Industry Average Movement | 4.9% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in DE Market | 10.1% |
| 10% least volatile stocks in DE Market | 2.5% |
Stable Share Price: 1K0's share price has been volatile over the past 3 months.
Volatility Over Time: 1K0's weekly volatility (17%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1993 | 224 | Fred Schwarzer | igmbio.com |
IGM Biosciences, Inc., a clinical-stage biotechnology company, develops Immunoglobulin M (IgM) antibodies for the treatment of cancer and autoimmune and inflammatory diseases. It develops Aplitabart, a Death Receptor 5 Agonist IgM antibody for the treatment of colorectal cancer; imvotamab, a CD20 x CD3 bispecific IgM antibody to treat myositis, as well as for the treatment of systemic lupus erythematosus and rheumatoid arthritis that is Phase Ib clinical trial; and IGM-2644, a bispecific T cell engaging IgM antibody targeting CD38 and CD3 proteins for the treatment of autoimmune diseases. IGM Biosciences, Inc. has a collaboration and license agreement with Genzyme Corporation to generate, develop, manufacture, and commercialize IgM antibodies.
IGM Biosciences, Inc. Fundamentals Summary
| 1K0 fundamental statistics | |
|---|---|
| Market cap | €518.03m |
| Earnings (TTM) | -€230.35m |
| Revenue (TTM) | €1.99m |
260.2x
P/S Ratio-2.2x
P/E RatioIs 1K0 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 1K0 income statement (TTM) | |
|---|---|
| Revenue | US$2.13m |
| Cost of Revenue | US$213.79m |
| Gross Profit | -US$211.66m |
| Other Expenses | US$34.76m |
| Earnings | -US$246.42m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -4.18 |
| Gross Margin | -9,937.09% |
| Net Profit Margin | -11,568.83% |
| Debt/Equity Ratio | 0% |
How did 1K0 perform over the long term?
See historical performance and comparison